An application of PEG-interferon and a protooncogene product targeting inhibitor in synergistic inhibition of tumors. Specifically, provided is use of an active ingredient combination. The active ingredient combination comprises PEG-interferon and a protooncogene product targeting inhibitor, and the combination is used for preparing a pharmaceutical composition for synergistic treatment of tumors. The active ingredient combination can synergistically inhibit the growth of tumors (especially lung, stomach, breast and liver cancers) effectively, and can significantly reduce toxic and side effects, and therefore can be widely used in targeted therapy of the tumors.

The invention is directed to methods of treating cancers using Interferon-ε (IFN-ε), wherein the IFN-ε includes various natural, synthetic and recombinant IFN-ε in compositions.

The invention is directed to methods of treating cancers using Interferon-ε (IFN-ε), wherein the IFN-ε includes various natural, synthetic and recombinant IFN-ε in compositions.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The present invention relates to the medical field, and in particular to the use of adefovir dipivoxil and a structural analog thereof for treating pseudorabies virus. In particular, the invention relates to the use of a compound as shown in formula (I), a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptable salt thereof for inhibiting the pseudorabies virus, treating pseudorabies virus infections or treating diseases related to pseudorabies virus infections.

##STR00001##

Disclosed herein are gastrointestinal tract (G1) bacteria and methods for treating or preventing an irradiation-induced intestinal damage in a subject, the methods comprising administering a G1 bacterium to the subject, wherein the G1 bacterium comprises a vector that comprises a polynucleotide encoding IL-22 and/or IFN-P, or a functional fragment thereof.

A method of reducing TET2 mutant allele burden in a subject, comprising: administering to a subject identified as having a TET2 mutation a 50 to 540 μg dose of a pegylated interferon-α at a regular interval of 2 to 8 weeks for a treatment period, the pegylated interferon-α being a conjugate of formula I:

##STR00001##

in which each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5, independently, is H, C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.2-5 alkynyl, aryl, heteraryl, C.sub.3-8 cycloalkyl, or C.sub.3-8 heterocycloalkyl; each of A.sub.1 and A.sub.2, independently, is a polymer moiety; each of G.sub.1, G.sub.2, and G.sub.3, independently, is a bond or a linking functional group; P is an interferon-α moiety; m is 0 or an integer of 1-10; and n is an integer of 1-10,
wherein the subject has a reduction in TET2 mutant allele burden at a second time point in the treatment period as compared to a first time point before or earlier in the treatment period.

Disclosed are methods and compositions for at least preventing, treating, inhibiting, or attenuating an Ebola virus infection of a subject. The methods comprise administering an effective amount of a composition as described herein to the subject thereby at least preventing, treating, inhibiting, or attenuating the Ebola virus infection of the subject. The compositions comprise a therapeutic double-stranded RNA (tdsRNA) and additional optional components such as an Ebola antigen.

This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV.

This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV.